Rhea-AI Summary
Diagonal Therapeutics (DIAG) appointed Jeremy Bender as chair of its board of directors, succeeding Michael Gladstone, who remains a director. Bender brings over 20 years of drug development and company leadership experience. He most recently led Day One Biopharmaceuticals through its first commercial launch and its acquisition by Servier in 2026.
Diagonal is enrolling patients in DIAMOND, a Phase 1/2 trial of DIAG723 for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder. The multicenter trial is randomized, double-blind and placebo-controlled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags